To test for possible spurious biases, we examined the association between SGLT2 inhibitors and the risk of chronic lower respiratory disease as a negative outcome control, with no prior knowledge suggesting a causal association. This evidence concerns the gene SLC5A2 and lower respiratory tract disorder.